Jonathan A. Polikoff
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 17
- HER2/EGFR in Cancer Research 7
- Cancer Immunotherapy and Biomarkers 5
- Colorectal Cancer Treatments and Studies 4
-
- Lymphoma Diagnosis and Treatment 10
- Co-authors
- Louis Fehrenbacher (11 shared papers)Paul Ruff (1 shared paper)Hans Prenen (1 shared paper)Radek Lakomý (1 shared paper)Eric Van Cutsem (3 shared papers)Guy A. Van Hazel (1 shared paper)R Castan (1 shared paper)Carmen Joseph Allegra (1 shared paper)
- Journals
- Journal of Clinical Oncology (11 papers)Annals of Oncology (10 papers)Blood (8 papers)Breast Cancer Research and Treatment (3 papers)The Lancet (2 papers)
- Partner nations
- United StatesItalyCanada
In The Last Decade
Jonathan A. Polikoff
49 papers receiving 11.1k citations
Jonathan A. Polikoff's Hit Papers
Peers
Comparison fields: 5 of 77
- Oncology 4.2k
- Gastroenterology 794
- Cancer Research 771
- Pulmonary and Respiratory Medicine 1.6k
- Genetics 306
Countries citing papers authored by Jonathan A. Polikoff
This map shows the geographic impact of Jonathan A. Polikoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Polikoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Polikoff more than expected).
Fields of papers citing papers by Jonathan A. Polikoff
This network shows the impact of papers produced by Jonathan A. Polikoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Polikoff. The network helps show where Jonathan A. Polikoff may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan A. Polikoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 49 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Hit paper breakdown → | 2016 | 3966 |
| 2 | Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Hit paper breakdown → | 2012 | 1128 |
| 3 | Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial Hit paper breakdown → | 2009 | 1080 |
| 4 | Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2020 | 676 |
| 5 | Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer Hit paper breakdown → | 2016 | 624 |
| 6 | 2012 | 433 | |
| 7 | 2010 | 395 | |
| 8 | 2011 | 345 | |
| 9 | Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Hit paper breakdown → | 2022 | 329 |
| 10 | 2019 | 326 | |
| 11 | 2010 | 268 | |
| 12 | 2016 | 213 | |
| 13 | 2012 | 190 | |
| 14 | 2005 | 158 | |
| 15 | 2013 | 149 | |
| 16 | 2013 | 115 | |
| 17 | 2011 | 104 | |
| 18 | 2021 | 99 | |
| 19 | 2013 | 98 | |
| 20 | Organizational barriers to physician participation in cancer clinical trials. | 2005 | 88 |
About Jonathan A. Polikoff
Jonathan A. Polikoff is a scholar working on Oncology, Pathology and Forensic Medicine, Cancer Research, Pulmonary and Respiratory Medicine and Gastroenterology, having authored 49 papers that have together received 11.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (10 papers), HER2/EGFR in Cancer Research (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Breast Cancer Treatment Studies (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Occupational and environmental lung diseases (3 papers), Prostate Cancer Treatment and Research (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (2 papers). The work is most often cited by research in Oncology (4.2k citations), Gastroenterology (794 citations), Cancer Research (771 citations), Pulmonary and Respiratory Medicine (1.6k citations) and Genetics (306 citations). Jonathan A. Polikoff has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include Louis Fehrenbacher, Paul Ruff, Hans Prenen, Radek Lakomý, Eric Van Cutsem, Guy A. Van Hazel, R Castan, Carmen Joseph Allegra, Alexia Tellier and Vladimir Mikhailovich Moiseyenko. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Blood, Breast Cancer Research and Treatment and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.